Merck has entered into a collaboration with Agilent Technologies with the aim of filling the industry gap in PAT for downstream processing.
Science and technology company, Merck, has entered into a collaboration with Agilent Technologies with the aim of filling the industry gap in process analytical technologies (PAT) for downstream processing (DSP), it was revealed in a June 14, 2022 press release.
Under the terms of the partnership, the companies will combine Merck’s bioprocess portfolio with Agilent Technologies’ advanced analytical products to extend real-time monitoring and automated process control of critical process parameters (CPPs) and critical quality attributes (CQAs) in DSP. PAT is key to enabling real-time release and Bioprocessing 4.0.
“The biopharmaceutical industry is on a rolling transformation to evolve and digitalize the next generation of bioprocessing to increase accessibility and lower the cost of biologics,” said Darren Verlenden, head of BioProcessing, Life Science business sector at Merck, in the press release. “By combining our advanced bioprocess portfolio with Agilent’s leading analytical solutions, we will be able to offer integrated capabilities for enhanced downstream process monitoring and control, bringing us one step closer to making the facility of the future a reality.”
“Integrating analytical capabilities and intelligence into bioprocessing enables the biopharma industry to accelerate biological drug development and manufacturing while supporting continuous manufacturing and real-time release,” added Stefan Schuette, vice president and general manager of Agilent´s Liquid Phase Separations Division. “This collaboration focuses on integrating Agilent’s new online liquid chromatography (LC) solution with Merck’s bioprocessing platforms and will support customers on their journey to develop and produce biological drugs faster, with greater confidence, and at lower cost.”
Source: Merck
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.